Press Releases
View printer-friendly version |
Bacterin’s OsteoSelect® DBM Putty Approved for Spinal Fusion Applications
As part of the regulatory approval process, Bacterin provided funding to
"We are proud to obtain another indication for use that will provide
Bacterin with additional marketing opportunities for the OsteoSelect®
DBM Putty product line," said
OsteoSelect® DBM Putty is a malleable bone grafting material comprised of demineralized bone matrix allograft combined with a polymer carrier material. The product was engineered using feedback from key opinion leaders in several orthopedic specialties, with a focus on providing solutions to the shortcomings inherent to other commercially available DBM products. The osteoinductive potential of every lot of OsteoSelect® is confirmed after sterilization in an animal model thus providing surgeons with a bone grafting solution that is both safe and biologically active.
About
Bacterin's Medical Device division develops, employs, and licenses coatings for various medical device applications. For further information, please visit www.bacterin.com.
Important Cautions Regarding Forward-looking Statements
This news release contains certain disclosures that may be deemed
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 that are subject to significant risks and
uncertainties. Forward-looking statements include statements that are
predictive in nature, that depend upon or refer to future events or
conditions, or that include words such as "continue," "efforts,"
"expects," "anticipates," "intends," "plans," "believes," "estimates,"
"projects," "forecasts," "strategy," "will," "goal," "target,"
"prospects," "potential," "optimistic," "confident," "likely,"
"probable" or similar expressions or the negative thereof. Statements of
historical fact also may be deemed to be forward-looking statements. We
caution that these statements by their nature involve risks and
uncertainties, and actual results may differ materially depending on a
variety of important factors, including, among others: our ability to
meet existing and anticipated contractual obligations, including
financial covenants and other obligations contained in our secured
lending facility; our ability to manage cash flow and achieve
profitability; our ability to regain compliance with the NYSE MKT
continued listing standards; our ability to develop, market, sell and
distribute desirable applications, products and services and to protect
our intellectual property and customer relationships; the ability of our
sales force to achieve expected results; the ability of our customers to
pay and the timeliness of such payments; our ability to obtain
additional equity or debt capital as and when needed; changes in
consumer demands and preferences; our ability to recruit a new CEO and
to attract and retain management and employees with appropriate skills
and expertise; our ability to successfully conclude certain pending
government investigations; the impact of changes in market, legal and
regulatory conditions and in the applicable business environment,
including actions of competitors; and other factors set forth in our
Source:
COCKRELL GROUP
Rich Cockrell, 877-889-1972
investorrelations@thecockrellgroup.com
cockrellgroup.com